Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study

Exclusion Criteria

• •1. Patients participating in other interventional clinical studies while taking regorafenib;
• •2. Patients with other malignant tumors within 5 years before regorafenib treatment, except for cured cervical carcinoma in situ, skin squamous cell carcinoma or basal cell carcinoma, early papillary thyroid carcinoma, etc.;
• •3. The investigator deems that there are other factors that are not suitable for patients who participate in this study.